Sudo Biosciences is focused on developing innovative therapeutics targeting the tyrosine kinase 2 (TYK2) pseudokinase domain, which plays a crucial role in cytokine signaling pathways associated with various immune-mediated inflammatory conditions. The company is advancing a pipeline of next-generation TYK2 inhibitors, including a brain-penetrant candidate aimed at treating multiple sclerosis and neurodegenerative diseases characterized by neuroinflammation. Additionally, Sudo is working on a topical candidate designed for immune-mediated dermatologic diseases, positioning itself to potentially offer first- and best-in-class treatment options in these therapeutic areas.

The leadership team at Sudo Biosciences comprises experienced professionals with extensive backgrounds in biopharmaceutical development and drug discovery. This includes experts in medicinal chemistry, clinical development, and business strategy, who collectively bring a wealth of knowledge from their previous roles in leading pharmaceutical companies. Their combined expertise is instrumental in driving the company's mission to create transformative medicines that can significantly improve patient outcomes in conditions linked to TYK2 signaling.

United States

Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.

Sudo Biosciences

Company Details